抗淋巴细胞球蛋白联合环孢霉素A治疗重型再生障碍性贫血的临床研究  

Antilymphocyte globulin combining with cyclosporine A in the treatment of severe aplastic anemia

作　　者：郑以州[1] 储榆林[1] 邵宗鸿[1] 张益枝[1] 陈桂彬[1] 

机构地区：[1]中国医学科学院,中国协和医科大学血液学研究所,血液病医院

出　　处：《中华血液学杂志》1999年第4期175-177,共3页Chinese Journal of Hematology

摘　　要：目的探讨进一步提高重型再生障碍性贫血（ＳＡＡ）疗效的方法。方法采用前瞻性同期对照研究方法，比较抗淋巴细胞球蛋白（ＡＬＧ）单用（ＮＩＳＴ方案）或联合环孢霉素Ａ（ＣｓＡ）（ＩＳＴ方案）治疗ＳＡＡ的疗效。结果ＩＳＴ方案组不仅疗效（８３７％）显著高于ＮＩＳＴ方案组（５７６％），且可降低早期死亡率、缩短脱离红细胞输注时间，治疗有效者骨髓ＢＦＵＥ和ＣＦＵＧＭ数量恢复更为良好。结论ＡＬＧ联合ＣｓＡ治疗ＳＡＡ疗效明显优于单用ＡＬＧ，且治疗有效者骨髓造血功能恢复更为完全。Objective To explore more effective regimen for severe aplastic anemia (SAA). Methods A prospective, randomized clinical trial was conducted to determine whether the outcome of SAA patients treated with the combination of antilymphocyte globulin(ALG) and cyclosporine A(CsA) (intensive immunosuppressive therapy, IIST) was better than that with ALG alone (non intensive immunosuppressive therapy, NIIST). Results The response rate of IIST group(83 7%) was significantly higher than that of NIIST group(57 6%),with a lower risk of early mortality and a shorter time to red cell transfusion independence.Furthermore,the recovery of bone marrow BFU E and CFU GM of the responding patients was more complete in IIST group than in NIIST group.Conclusions The treatment outcome was better with IIST than with NIIST for SAA.

关 键 词：再生障碍性贫血 环孢菌素 ALG 药物疗法 

分 类 号：R556.505[医药卫生—血液循环系统疾病]